on-demand

Houston-area early childhood education startup launches app to find at-home educators

A Houston startup is using technology to provide on-demand educators. Educational First Steps/Facebook

A Houston-area early childhood care and education startup and MassChallenge Texas in Austin 2020 participant, recently launched its 24/7 on-demand, two-sided marketplace platform that provides benefits for both parents and guardians or child care operators who need qualified educators quickly.

Due to the ongoing coronavirus pandemic, many parents are still juggling a full-time job and childcare at the same time. The launch of a marketplace platform app like OpenStaff aims to solve that problem, providing temporary or permanent childcare and teacher personnel to families and childcare operators across the Houston area, until children are able to safely go back to their daycare centers or classrooms.

"OpenStaff's Educational Mentors provide a structure that allows your child and family to retain some much-needed normalcy," says Jose Rodriguez, CEO and founder. "Our fully certified early childhood teachers and practitioners use their knowledge and experience to further a child's education while providing a safe, fun, and caring learning experience at home."

The app was launched on iOS platforms and is actively being user tested while they continue to build their database of qualified early childhood educators and substitute teachers for families and centers. All their educators comply with child care licensing regulations, completing a rigorous vetting process before they are allowed to join the platform.

"When you hire someone through our platform," says Rodriguez, "you have the peace of mind and our assurance that this teacher has been qualified, certified, background checked, and licensed in order to become a member of the OpenStaff educator community."

The early-stage startup came about from Rodriguez's first business, a childcare center that he took over six years ago with his wife. For them, the biggest challenge in this industry was staff management, dealing with unplanned absences would change plans drastically, sometimes changing teaching plans or restructuring classes.

"Even though we have an amazing team, sometimes life happens and they are not available to come into work that morning," says Rodriguez. "It was very stressful for office managers and owners as well as the rest of the team and if we were unable to find anyone to cover, even my wife or I would end up in the classroom."

That's when he started using staffing agencies for unplanned temporary workers but those, he says, are time-consuming and overpriced.

"We wanted to offer a different option that really works for everyone, not just parents during this crisis but also daycare centers," says Rodriguez. "Our app provides an open marketplace where centers can post a job by simply using their phone and receive applicants in minutes."

OpenStaff is currently focused on taking its service to the market, using the data and feedback as a way to make their offering better to then accelerate and scale, as many childcare centers continue to struggle to operate or find a sense of normalcy amid the social distancing measures that are the new normal.

"Many childcare centers have been hard hit during the coronavirus pandemic," says Rodriguez. "Many are struggling, closing their business, or operating with limited staff and children. With our app, we can, in the short term, help Houston families by providing quality education for their children."

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted